Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.
Patients 18 years of age or older;
Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening;
Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time;
Patients who are willing to sign the informed consent form.
Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium);
Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution;
Patients with other contraindications specified in the prescribing information;
Patients concurrently participating in other clinical studies;
Chongqing Genrix Biopharmaceutical Co., Ltd
Lead sponsor
Xiangya Hospital of Central South University
Collaborator